Healthcare Technology Stocks Q4 Recap: Benchmarking GoodRx (NASDAQ:GDRX)

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare technology stocks fared in Q4, starting with GoodRx (NASDAQ:GDRX).

Healthcare technology companies develop software, data analytics, and digital platforms supporting clinical operations, administrative functions, and patient engagement across healthcare systems. Tailwinds include healthcare digitization driving demand for electronic health records, telehealth platforms, and AI-powered diagnostic tools. Regulatory incentives promote interoperability and data sharing, while labor shortages increase automation demand. Headwinds include lengthy sales cycles with risk-averse healthcare buyers, complex regulatory requirements including data privacy compliance, and integration challenges with legacy systems. Competition from established technology giants entering healthcare and reimbursement uncertainties for digital health solutions add market complexity.Add to Conversation

The 7 healthcare technology stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was in line.

Luckily, healthcare technology stocks have performed well with share prices up 23.6% on average since the latest earnings results.

Weakest Q4: GoodRx (NASDAQ:GDRX)

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ:GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

GoodRx reported revenues of $194.8 million, down 1.9% year on year. This print exceeded analysts’ expectations by 0.8%. Despite the top-line beat, it was still a softer quarter for the company with full-year revenue and EBITDA guidance missing analysts’ expectations significantly.

Unsurprisingly, the stock is down 4.5% since reporting and currently trades at $2.34.

Read our full report on GoodRx here, it’s free.

Best Q4: Privia Health (NASDAQ:PRVA)

Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ:PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.

Privia Health reported revenues of $541.2 million, up 17.4% year on year, outperforming analysts’ expectations by 4.8%. The business had a stunning quarter with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

The market seems content with the results as the stock is up 4.2% since reporting. It currently trades at $23.61.

Is now the time to buy Privia Health? Access our full analysis of the earnings results here, it’s free.

Omnicell (NASDAQ:OMCL)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Omnicell reported revenues of $314 million, up 2.3% year on year, in line with analysts’ expectations. It was a mixed quarter as it posted EBITDA guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates.

Omnicell delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 21.1% since the results and currently trades at $36.84.

Read our full analysis of Omnicell’s results here.

Evolent Health (NYSE:EVH)

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Evolent Health reported revenues of $468.7 million, down 27.5% year on year. This result met analysts’ expectations. Overall, it was a strong quarter as it also recorded a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Evolent Health had the slowest revenue growth among its peers. The stock is up 22.1% since reporting and currently trades at $3.13.

Read our full, actionable report on Evolent Health here, it’s free.

Hims & Hers Health (NYSE:HIMS)

Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.

Hims & Hers Health reported revenues of $617.8 million, up 28.4% year on year. This print was in line with analysts’ expectations. Taking a step back, it was a mixed quarter as it also produced full-year revenue guidance exceeding analysts’ expectations but revenue guidance for next quarter missing analysts’ expectations significantly.

Hims & Hers Health achieved the highest full-year guidance raise among its peers. The company added 40,000 customers to reach a total of 2.51 million. The stock is up 94.3% since reporting and currently trades at $30.14.

Read our full, actionable report on Hims & Hers Health here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.